BioSpace News Archive

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced it will release its financial results for the fourth quarter and full year of 2020 on Thursday, March 18, 2021.

Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the fourth quarter and year ended December 31, 2020 will be released after the close of market on Thursday, March 11, 2021.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced financial results for its fourth quarter and full-year ended December 31, 2020.

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Andrew Sinclair, Ph.D., to its board of directors.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021.

Diffusion Pharmaceuticals Inc., an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced that Robert J. Cobuzzi, Ph.D., CEO of Diffusion, will present at the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, announced that the company will hold a conference call and live webcast on Wednesday, March 10, 2021 at 4:30 p.m. Eastern Time to review its 2020 financial results and provide a business update.

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012.